- Home
- KLRS vs ICMB Comparison
KLRS vs ICMB Comparison
Compare KLRS & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | ICMB |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 33.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | KLRS | ICMB |
|---|---|---|
| Price | $8.76 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $20.67 | N/A |
| AVG Volume (30 Days) | ★ 55.5K | 31.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 22.41% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.75 |
| P/E Ratio | ★ N/A | $58.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $2.30 |
| 52 Week High | $11.90 | $3.38 |
Technical Indicators
Market Signals| Indicator | KLRS | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 15.13 |
| Support Level | $8.27 | N/A |
| Resistance Level | $8.80 | $3.00 |
| Average True Range (ATR) | 0.83 | 0.14 |
| MACD | -0.18 | -0.10 |
| Stochastic Oscillator | 0.00 | 14.36 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.